Skip to main content

Table 4 Secondary outcomes in the ICS cessation and control groups in the 1-year outcome period

From: Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study

  Total
No. 5230
Control
No. 4184
ICS cessation
No. 1046
Exacerbations    
 Managed in primary care 0.86 (± 1.33) 0.86 (± 1.32) 0.90 (± 1.35)
 Resulting in A&E attendance 0.09 (± 0.38) 0.09 (± 0.36) 0.11 (± 0.45)
 Total exacerbations 0.96 (± 1.42) 0.94 (± 1.41) 1.01 (± 1.46)
Change in FEV1    
 Baseline FEV1 (L) 1.39 (± 0.57) 1.36 (± 0.56) 1.49 (± 0.60)
 Outcome FEV1 (L) 1.35 (± 0.58) 1.33 (± 0.58) 1.43 (± 0.60)
 Annualised change in FEV1 (in mL) − 25.1 (± 248.1) − 18.8 (± 253.2) − 48.8 (± 226.4)
 Missing (n (%)) 3777 (72.2%) 3035 (72.5%) 742 (70.9%)
CAT score in outcome yeara
 < 10 183 (24.0%) 135 (23.9%) 48 (24.4%)
 ≥ 10 580 (76.0%) 431 (76.1%) 149 (75.6%)
 Mean (SD) 16.6 (± 9.6) 16.8 (± 9.9) 16.2 (± 8.8)
 Missing 4467 (85.4%) 3618 (86.5%) 849 (81.2%)
mMRC dyspnea score in outcome yeara
 0–1 1345 (36.2%) 1072 (35.6%) 273 (38.7%)
 2–4 2371 (63.8%) 1938 (64.4%) 433 (61.3%)
 Mean (SD) 1.9 (± 1.0) 2.0 (± 1.0) 1.9 (± 1.0)
 Missing 1514 (28.9%) 1174 (28.1%) 340 (32.5%)
  1. aFirst score recorded following IPD is used. Values given are mean (SD)